300552-41-4

Usage

Uses

Used in Pharmaceutical Development:
7-Benzyl-4-Chloro-2-Methyl-5,6,7,8-Tetrahydropyrido[3,4-D]pyrimidine is used as a potential candidate in pharmaceutical development for its possible therapeutic effects. Its unique structure with various functional groups may offer opportunities for further research and development into new drugs with specific medical applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 7-Benzyl-4-Chloro-2-Methyl-5,6,7,8-Tetrahydropyrido[3,4-D]pyrimidine is utilized as a subject of study to explore its potential biological activities. 7-BENZYL-4-CHLORO-2-METHYL-5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIMIDINE's structure may provide insights into the design of new molecules with desired pharmacological properties, contributing to the advancement of drug discovery and development.

Upstream product

• 124-42-5 acetamidine hydrochloride 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 
• 62259-92-1 7-benzyl-2-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one 
• 745066-54-0 2-methyl-7-(phenylmethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4 (4aH)-one 

Downstream Products

• 745066-53-9 2-methyl-7-(phenylmethyl)-4-piperidin-1-yl-5,6,7,8-tetrahydropyrido [3,4-d] pyrimidine 
• 300552-42-5 7-benzyl-2-methyl-4-phenyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine 

Relevant academic research and scientific papers

Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore

6,6-Fused ring systems including tetrahydroisoquinolines and tetrahydropyrido[3,4-d]pyrimidines have been explored as possible replacements for the piperazine benzamide portion of the HIV-1 attachment inhibitor BMS-663068. In initial studies, the tetrahydroisoquinoline compounds demonstrate sub-nanomolar activity in a HIV-1 pseudotype viral infection assay used as the initial screen for inhibitory activity. Analysis of SARs and approaches to optimization for an improved drug-like profile are examined herein.

Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof

Compounds having formula (I) or formula (II) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A, N, X, Y, R1, R2 and R3 are as defined in the specification. These compounds are particul

ANTIPARASITIC TERPENE ALKALOIDS

The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.

Sorbitol dehydrogenase inhibitors

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2and R3are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.